Pharming Group (NASDAQ:PHAR) Price Target Raised to $39.00

Pharming Group (NASDAQ:PHAR) had its price objective increased by Oppenheimer from $30.00 to $39.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

PHAR has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Friday. Jefferies Financial Group initiated coverage on Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Pharming Group Trading Up 0.3 %

Shares of Pharming Group stock opened at $8.77 on Friday. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.80. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The stock has a market cap of $596.63 million, a PE ratio of -33.73 and a beta of -0.10. The firm has a fifty day moving average price of $8.99 and a 200 day moving average price of $8.59.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.